1.Bollum FJ, Potter VR. Nucleic acid metabolism in regenerating rat liver. VI. Soluble enzymes which convert thymidine to thymidine phosphates and DNA. Cancer research. 1959;19(5):561–5.
2.Weber G, Nagai M, Natsumeda Y, Ichikawa S, Nakamura H, Eble JN, et al. Regulation of de novo and salvage pathways in chemotherapy. Advances in enzyme regulation. 1991;31:45–67.
3.Engelking LR. Chapter 15 - Purine Biosynthesis. In: Engelking LR, editor. Textbook of Veterinary Physiological Chemistry (Third Edition). Boston: Academic Press; 2015. p. 88–92.
4.Puigserver P. Chapter 7 - Signaling Transduction and Metabolomics. In: Hoffman R, Benz EJ, Silberstein LE, Heslop HE, Weitz JI, Anastasi J, et al., editors. Hematology (Seventh Edition): Elsevier; 2018. p. 68–78.
5.Chen YL, Eriksson S, Chang ZF. Regulation and functional contribution of thymidine kinase 1 in repair of DNA damage. The Journal of biological chemistry. 2010;285(35):27327–35.
6.Munch-Petersen B, Cloos L, Jensen HK, Tyrsted G. Human thymidine kinase 1. Regulation in normal and malignant cells. Advances in enzyme regulation. 1995;35:69–89.
7.Topolcan O, Holubec L. The role of thymidine kinase in cancer diseases. Expert Opinion on Medical Diagnostics. 2008;2(2):129–41.
8.Zhou J, He E, Skog S. The proliferation marker thymidine kinase 1 in clinical use. Mol Clin Oncol. 2013;1(1):18–28.
9.Fischer M, Quaas M, Steiner L, Engeland K. The p53-p21-DREAM-CDE/CHR pathway regulates G2/M cell cycle genes. Nucleic Acids Res. 2016;44(1):164–74.
10.Engeland K. Cell cycle arrest through indirect transcriptional repression by p53: I have a DREAM. Cell death and differentiation. 2018;25(1):114–32.
11.Cai Z, Liu Q. Cell Cycle Regulation in Treatment of Breast Cancer. Advances in experimental medicine and biology. 2017;1026:251–70.
12.Collins K, Jacks T, Pavletich NP. The cell cycle and cancer. Proceedings of the National Academy of Sciences. 1997;94(7):2776.
13.Otto T, Sicinski P. Cell cycle proteins as promising targets in cancer therapy. Nature reviews Cancer. 2017;17(2):93–115.
14.Alegre MM, Robison RA, O’Neill KL. Thymidine kinase 1 upregulation is an early event in breast tumor formation. J Oncol. 2012;2012:575647-.
15.Ning S, Wei W, Li J, Hou B, Zhong J, Xie Y, et al. Clinical significance and diagnostic capacity of serum TK1, CEA, CA 19–9 and CA 72–4 levels in gastric and colorectal cancer patients. J Cancer. 2018;9(3):494–501.
16.Jiang ZF, Wang M, Xu JL. Thymidine kinase 1 combined with CEA, CYFRA21–1 and NSE improved its diagnostic value for lung cancer. Life sciences. 2018;194:1–6.
17.Xiang Y, Zeng H, Liu X, Zhou H, Luo L, Duan C, et al. Thymidine kinase 1 as a diagnostic tumor marker is of moderate value in cancer patients: A meta-analysis. Biomedical reports. 2013;1(4):629–37.
18.Tilli TM, Carels N, Tuszynski JA, Pasdar M. Validation of a network-based strategy for the optimization of combinatorial target selection in breast cancer therapy: siRNA knockdown of network targets in MDA-MB–231 cells as an in vitro model for inhibition of tumor development. Oncotarget. 2016;7(39)(1949–2553 (Electronic)):63189–203.
19.Song ZY, Chao F, Zhuo Z, Ma Z, Li W, Chen G. Identification of hub genes in prostate cancer using robust rank aggregation and weighted gene co-expression network analysis. AGING. 2019;11(13)(1945–4589 (Electronic)):4736–56.
20.Alshabi AM, Vastrad B, Shaikh IA, Vastrad C. Identification of important invasion and proliferation related genes in adrenocortical carcinoma. Med Oncol. 2019;36(9):73.
21.Chandrashekar DS, Bashel B, Balasubramanya SAH, Creighton CJ, Ponce-Rodriguez I, Chakravarthi B, et al. UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses. Neoplasia (New York, NY). 2017;19(8):649–58.
22.Zhu Y, Qiu P, Ji Y. TCGA-Assembler: open-source software for retrieving and processing TCGA data. Nature Methods. 2014;11(6):599–600.
23.Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 2012;483:603.
24.Townsend MH, Felsted AM, Piccolo SR, Robison RA, O’Neill KL. Metastatic colon adenocarcinoma has a significantly elevated expression of IL–10 compared with primary colon adenocarcinoma tumors. Cancer Biology & Therapy. 2018;19(10):913–20.
25.Schneider CA, Rasband WS, Eliceiri KW. NIH Image to ImageJ: 25 years of image analysis. Nature Methods. 2012;9(7):671–5.
26.Li T, Fan J, Wang B, Traugh N, Chen Q, Liu JS, et al. TIMER: A Web Server for Comprehensive Analysis of Tumor-Infiltrating Immune Cells. Cancer research. 2017;77(21):e108-e10.
27.Bailey MH, Tokheim C, Porta-Pardo E, Sengupta S, Bertrand D, Weerasinghe A, et al. Comprehensive Characterization of Cancer Driver Genes and Mutations. Cell. 2018;173(2):371–85.e18.
28.Belinky F, Nativ N, Stelzer G, Zimmerman S, Iny Stein T, Safran M, et al. PathCards: multi-source consolidation of human biological pathways. Database. 2015;2015.
29.Xiao A, Cheng Z, Kong L, Zhu Z, Lin S, Gao G, et al. CasOT: a genome-wide Cas9/gRNA off-target searching tool. Bioinformatics (Oxford, England). 2014;30(8):1180–2.
30.Shalem O, Sanjana NE, Zhang F. High-throughput functional genomics using CRISPR–Cas9. Nature Reviews Genetics. 2015;16:299.
31.Ran FA, Cong L, Yan WX, Scott DA, Gootenberg JS, Kriz AJ, et al. In vivo genome editing using Staphylococcus aureus Cas9. Nature. 2015;520:186.
32.Haeussler M, Schönig K, Eckert H, Eschstruth A, Mianné J, Renaud J-B, et al. Evaluation of off-target and on-target scoring algorithms and integration into the guide RNA selection tool CRISPOR. Genome Biology. 2016;17(1):148.
33.Xu H, Xiao T, Chen CH, Li W, Meyer CA, Wu Q, et al. Sequence determinants of improved CRISPR sgRNA design. Genome research. 2015;25(8):1147–57.
34.Cancer Genome Atlas N. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490(7418):61–70.
35.Cancer Genome Atlas Research N, Weinstein JN, Collisson EA, Mills GB, Shaw KRM, Ozenberger BA, et al. The Cancer Genome Atlas Pan-Cancer analysis project. Nat Genet. 2013;45(10):1113–20.
36.Mounir M, Lucchetta M, Silva TC, Olsen C, Bontempi G, Chen X, et al. New functionalities in the TCGAbiolinks package for the study and integration of cancer data from GDC and GTEx. PLoS computational biology. 2019;15(3):e1006701.
37.Mi H, Muruganujan A, Ebert D, Huang X, Thomas PD. PANTHER version 14: more genomes, a new PANTHER GO-slim and improvements in enrichment analysis tools. Nucleic Acids Res. 2018;47(D1):D419-D26.
38.Jagarlamudi KK, Shaw M. Thymidine kinase 1 as a tumor biomarker: technical advances offer new potential to an old biomarker. Biomarkers in Medicine. 2018;12(9):1035–48.
39.Haveman J, Sigmond J, van Bree C, Franken NA, Koedooder C, Peters GJ. Time course of enhanced activity of deoxycytidine kinase and thymidine kinase 1 and 2 in cultured human squamous lung carcinoma cells, SW–1573, induced by gamma-irradiation. Oncology reports. 2006;16(4):901–5.
40.Seyfried TN, Huysentruyt LC. On the origin of cancer metastasis. Crit Rev Oncog. 2013;18(1–2):43–73.
41.Zhu X, Shi C, Peng Y, Yin L, Tu M, Chen Q, et al. Thymidine kinase 1 silencing retards proliferative activity of pancreatic cancer cell via E2F1-TK1-P21 axis. Cell Prolif. 2018;51(3):e12428.
42.O’Neill KL, Zhang F, Li H, Fuja DG, Murray BK. Thymidine kinase 1—A prognostic and diagnostic indicator in ALL and AML patients. Leukemia. 2007;21(3):560–3.
43.Zheng B, Fiumara P, Li YV, Georgakis G, Snell V, Younes M, et al. MEK/ERK pathway is aberrantly active in Hodgkin disease: a signaling pathway shared by CD30, CD40, and RANK that regulates cell proliferation and survival. Blood. 2003;102(3):1019–27.
44.Flusberg DA, Sorger PK. Surviving apoptosis: life-death signaling in single cells. Trends Cell Biol. 2015;25(8):446–58.
45.Li Y, Barbash O, Diehl JA. 11 - Regulation of the Cell Cycle. In: Mendelsohn J, Gray JW, Howley PM, Israel MA, Thompson CB, editors. The Molecular Basis of Cancer (Fourth Edition). Philadelphia: Content Repository Only!; 2015. p. 165–78.e2.
46.Barbash O, Alan Diehl J. Chapter 13 - Regulation of the Cell Cycle. In: Mendelsohn J, Howley PM, Israel MA, Gray JW, Thompson CB, editors. The Molecular Basis of Cancer (Third Edition). Philadelphia: W. B. Saunders; 2008. p. 177–88.
47.Cui Y, Riedlinger G, Miyoshi K, Tang W, Li C, Deng C-X, et al. Inactivation of Stat5 in mouse mammary epithelium during pregnancy reveals distinct functions in cell proliferation, survival, and differentiation. Molecular and cellular biology. 2004;24(18):8037–47.
48.Lawlor MA, Alessi DR. PKB/Akt: a key mediator of cell proliferation, survival and insulin responses? Journal of cell science. 2001;114(Pt 16):2903–10.
49.Meloche S, Pouyssegur J. The ERK1/2 mitogen-activated protein kinase pathway as a master regulator of the G1- to S-phase transition. Oncogene. 2007;26(22):3227–39.
50.Yu JSL, Cui W. Proliferation, survival and metabolism: the role of PI3K/AKT/mTOR signalling in pluripotency and cell fate determination. Development. 2016;143(17):3050.
51.Wu F, Zhou L, Jin W, Yang W, Wang Y, Yan B, et al. Anti-Proliferative and Apoptosis-Inducing Effect of Theabrownin against Non-small Cell Lung Adenocarcinoma A549 Cells. Front Pharmacol. 2016;7:465-.
52.An S, Zheng Y, Bleu T. Sphingosine 1-phosphate-induced cell proliferation, survival, and related signaling events mediated by G protein-coupled receptors Edg3 and Edg5. The Journal of biological chemistry. 2000;275(1):288–96.
53.Zhang Y, Hunter T. Roles of Chk1 in cell biology and cancer therapy. International journal of cancer. 2014;134(5):1013–23.